{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T08:06:14Z","timestamp":1787731574508,"version":"build-2784847793"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T00:00:00Z","timestamp":1606089600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T00:00:00Z","timestamp":1606089600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008672","name":"Wilhelm Sander-Stiftung","doi-asserted-by":"crossref","award":["2015.191.1"],"award-info":[{"award-number":["2015.191.1"]}],"id":[{"id":"10.13039\/100008672","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100008672","name":"Wilhelm Sander-Stiftung","doi-asserted-by":"crossref","award":["2015.171.1"],"award-info":[{"award-number":["2015.171.1"]}],"id":[{"id":"10.13039\/100008672","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Projekt DEAL"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>MiRNAs act as negative regulators of gene expression through target mRNA degradation or inhibition of its translation. In cancer, several miRNAs are upregulated and play crucial roles in tumorigenesis, making the inhibition of these oncomiRs an interesting therapeutic approach. This can be achieved by directly complementary single-stranded anti-miRNA oligonucleotides (antimiRs). A major bottleneck in antimiR therapy, however, is their efficient delivery. The nanoparticle formation with polyethylenimine (PEI) may be particularly promising, based on the PEI\u2019s ability to electrostatically interact with oligonucleotides. This leads to their protection and supports delivery. In the present study, we explore for the first time PEI for antimiR formulation and delivery. We use the branched low molecular weight PEI F25-LMW for the complexation of different antimiRs, and analyse tumor- and metastasis-inhibitory effects of PEI\/antimiR complexes in different tumor models.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In prostate carcinoma, transfection of antimiRs against miR-375 and miR-141 leads to tumor cell inhibition in 2D- and 3D-models. More importantly, an in vivo tumor therapy study in prostate carcinoma xenografts reveals anti-tumor effects of the PEI\/antimiR complexes. In advanced melanoma and metastasis, we identify by a microRNA screen miR-150 as a particularly relevant oncomiR candidate, and validate this result in vitro and in vivo. Again, the systemic application of PEI\/antimiR complexes inhibiting this miRNA, or the previously described antimiR-638, leads to profound tumor growth inhibition. These effects are associated with the upregulation of direct miRNA target genes. In a melanoma metastasis mouse model, anti-metastatic effects of PEI\/antimiR treatment are observed as well.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>We thus describe PEI-based complexes as efficient platform for antimiR therapy, as determined in two different tumor entities using in vivo models of tumor growth or metastasis. Our study also highlights the therapeutic relevance of miR-375, miR-141, miR-150 and miR-638 as target miRNAs for antimiR-mediated inhibition.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12951-020-00728-w","type":"journal-article","created":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T14:05:23Z","timestamp":1606140323000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Nanoparticle-complexed antimiRs for inhibiting tumor growth and metastasis in prostate carcinoma and melanoma"],"prefix":"10.1186","volume":"18","author":[{"given":"Manfred","family":"Kunz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine","family":"Brandl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Animesh","family":"Bhattacharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Nobereit-Siegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Ewe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Weirauch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doreen","family":"Hering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Reinert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Kalwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Guzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Weigelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Wach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helge","family":"Taubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2778-6256","authenticated-orcid":false,"given":"Achim","family":"Aigner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,23]]},"reference":[{"issue":"2","key":"728_CR1","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.cell.2009.01.002","volume":"136","author":"DP Bartel","year":"2009","unstructured":"Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136(2):215\u201333.","journal-title":"Cell"},{"key":"728_CR2","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/978-1-4939-0882-0_12","volume":"1169","author":"T Kaeuferle","year":"2014","unstructured":"Kaeuferle T, Bartel S, Dehmel S, Krauss-Etschmann S. MicroRNA methodology: advances in miRNA technologies. Methods Mol Biol. 2014;1169:121\u201330.","journal-title":"Methods Mol Biol"},{"issue":"3","key":"728_CR3","doi-asserted-by":"publisher","first-page":"D152","DOI":"10.1093\/nar\/gkq1027","volume":"39","author":"A Kozomara","year":"2011","unstructured":"Kozomara A, Griffiths-Jones S. miRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res. 2011;39(3):D152\u20137.","journal-title":"Nucleic Acids Res."},{"issue":"5","key":"728_CR4","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s00109-010-0716-0","volume":"89","author":"A Aigner","year":"2011","unstructured":"Aigner A. MicroRNAs (miRNAs) in cancer invasion and metastasis: therapeutic approaches based on metastasis-related miRNAs. J Mol Med. 2011;89(5):445\u201357.","journal-title":"J Mol Med"},{"key":"728_CR5","doi-asserted-by":"crossref","unstructured":"Shah V, Shah J. Recent trends in targeting miRNAs for cancer therapy. J Pharm Pharmacol. 2020.","DOI":"10.1111\/jphp.13351"},{"issue":"10","key":"728_CR6","first-page":"775","volume":"9","author":"R Garzon","year":"2010","unstructured":"Garzon R, Marcucci G, Croce CM. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev. 2010;9(10):775\u201389.","journal-title":"Nat Rev"},{"issue":"12","key":"728_CR7","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1038\/gt.2011.100","volume":"18","author":"KA Lennox","year":"2011","unstructured":"Lennox KA, Behlke MA. Chemical modification and design of anti-miRNA oligonucleotides. Gene Ther. 2011;18(12):1111\u201320.","journal-title":"Gene Ther"},{"issue":"9","key":"728_CR8","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1007\/s11095-010-0156-0","volume":"27","author":"KA Lennox","year":"2010","unstructured":"Lennox KA, Behlke MA. A direct comparison of anti-microRNA oligonucleotide potency. Pharm Res. 2010;27(9):1788\u201399.","journal-title":"Pharm Res"},{"issue":"7068","key":"728_CR9","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/nature04303","volume":"438","author":"J Krutzfeldt","year":"2005","unstructured":"Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M, et al. Silencing of microRNAs in vivo with \u201cantagomirs.\u201d Nature. 2005;438(7068):685\u20139.","journal-title":"Nature"},{"issue":"42","key":"728_CR10","doi-asserted-by":"publisher","first-page":"13233","DOI":"10.1021\/bi0485732","volume":"43","author":"B Vester","year":"2004","unstructured":"Vester B, Wengel J. LNA (locked nucleic acid): high-affinity targeting of complementary RNA and DNA. Biochemistry. 2004;43(42):13233\u201341.","journal-title":"Biochemistry"},{"key":"728_CR11","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/B978-0-12-407676-1.00002-0","volume":"82","author":"KE Lundin","year":"2013","unstructured":"Lundin KE, Hojland T, Hansen BR, Persson R, Bramsen JB, Kjems J, et al. Biological activity and biotechnological aspects of locked nucleic acids. Adv Genet. 2013;82:47\u2013107.","journal-title":"Adv Genet"},{"issue":"2","key":"728_CR12","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/nbt.1602","volume":"28","author":"SC Semple","year":"2010","unstructured":"Semple SC, Akinc A, Chen J, Sandhu AP, Mui BL, Cho CK, et al. Rational design of cationic lipids for siRNA delivery. Nat Biotechnol. 2010;28(2):172\u20136.","journal-title":"Nat Biotechnol"},{"key":"728_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.29584","author":"A Kardani","year":"2020","unstructured":"Kardani A, Yaghoobi H, Alibakhshi A, Khatami M. Inhibition of miR-155 in MCF-7 breast cancer cell line by gold nanoparticles functionalized with antagomir and AS1411 aptamer. J Cell Physiol. 2020. https:\/\/doi.org\/10.1002\/jcp.29584.","journal-title":"J Cell Physiol."},{"key":"728_CR14","doi-asserted-by":"publisher","first-page":"7727","DOI":"10.2147\/IJN.S182384","volume":"13","author":"Z Naseri","year":"2018","unstructured":"Naseri Z, Oskuee RK, Jaafari MR, Forouzandeh MM. Exosome-mediated delivery of functionally active miRNA-142-3p inhibitor reduces tumorigenicity of breast cancer in vitro and in vivo. Int J Nanomed. 2018;13:7727\u201347.","journal-title":"Int J Nanomed"},{"issue":"16","key":"728_CR15","doi-asserted-by":"publisher","first-page":"7297","DOI":"10.1073\/pnas.92.16.7297","volume":"92","author":"O Boussif","year":"1995","unstructured":"Boussif O, Lezoualc\u2019h F, Zanta MA, Mergny MD, Scherman D, Demeneix B, et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci USA. 1995;92(16):7297\u2013301.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"728_CR16","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/sj.gt.3300454","volume":"4","author":"MX Tang","year":"1997","unstructured":"Tang MX, Szoka FC. The influence of polymer structure on the interactions of cationic polymers with DNA and morphology of the resulting complexes. Gene Ther. 1997;4(8):823\u201332.","journal-title":"Gene Ther"},{"issue":"3","key":"728_CR17","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1002\/(SICI)1097-4636(19990605)45:3<268::AID-JBM15>3.0.CO;2-Q","volume":"45","author":"WT Godbey","year":"1999","unstructured":"Godbey WT, Wu KK, Mikos AG. Size matters: molecular weight affects the efficiency of poly(ethylenimine) as a gene delivery vehicle. J Biomed Mater Res. 1999;45(3):268\u201375.","journal-title":"J Biomed Mater Res"},{"issue":"2","key":"728_CR18","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.jconrel.2006.02.009","volume":"112","author":"S Werth","year":"2006","unstructured":"Werth S, Urban-Klein B, Dai L, Hobel S, Grzelinski M, Bakowsky U, et al. A low molecular weight fraction of polyethylenimine (PEI) displays increased transfection efficiency of DNA and siRNA in fresh or lyophilized complexes. J Control Release. 2006;112(2):257\u201370.","journal-title":"J Control Release"},{"issue":"24","key":"728_CR19","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1038\/sj.gt.3301839","volume":"9","author":"A Aigner","year":"2002","unstructured":"Aigner A, Fischer D, Merdan T, Brus C, Kissel T, Czubayko F. Delivery of unmodified bioactive ribozymes by an RNA-stabilizing polyethylenimine (LMW-PEI) efficiently down-regulates gene expression. Gene Ther. 2002;9(24):1700\u20137.","journal-title":"Gene Ther"},{"issue":"5","key":"728_CR20","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/sj.gt.3302425","volume":"12","author":"B Urban-Klein","year":"2005","unstructured":"Urban-Klein B, Werth S, Abuharbeid S, Czubayko F, Aigner A. RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther. 2005;12(5):461\u20136.","journal-title":"Gene Ther"},{"issue":"15","key":"728_CR21","doi-asserted-by":"publisher","first-page":"5214","DOI":"10.1158\/0008-5472.CAN-10-4645","volume":"71","author":"AF Ibrahim","year":"2011","unstructured":"Ibrahim AF, Weirauch U, Thomas M, Grunweller A, Hartmann RK, Aigner A. MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma. Cancer Res. 2011;71(15):5214\u201324.","journal-title":"Cancer Res"},{"issue":"8","key":"728_CR22","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.4161\/rna.21165","volume":"9","author":"M Thomas","year":"2012","unstructured":"Thomas M, Lange-Grunweller K, Dayyoub E, Bakowsky U, Weirauch U, Aigner A, et al. PEI-complexed LNA antiseeds as miRNA inhibitors. RNA Biol. 2012;9(8):1088\u201398.","journal-title":"RNA Biol"},{"issue":"8","key":"728_CR23","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1136\/gut.2009.189720","volume":"59","author":"S Ripka","year":"2010","unstructured":"Ripka S, Neesse A, Riedel J, Bug E, Aigner A, Poulsom R, et al. CUX1: target of Akt signalling and mediator of resistance to apoptosis in pancreatic cancer. Gut. 2010;59(8):1101\u201310.","journal-title":"Gut"},{"issue":"3","key":"728_CR24","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/jgm.1431","volume":"12","author":"S Hobel","year":"2010","unstructured":"Hobel S, Koburger I, John M, Czubayko F, Hadwiger P, Vornlocher HP, et al. Polyethylenimine\/small interfering RNA-mediated knockdown of vascular endothelial growth factor in vivo exerts anti-tumor effects synergistically with Bevacizumab. J Gene Med. 2010;12(3):287\u2013300.","journal-title":"J Gene Med"},{"issue":"9","key":"728_CR25","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1002\/emmm.201202406","volume":"5","author":"V Hampl","year":"2013","unstructured":"Hampl V, Martin C, Aigner A, Hoebel S, Singer S, Frank N, et al. Depletion of the transcriptional coactivators Megakaryoblastic Leukemia 1 and 2 abolishes hepatocellular carcinoma xenograft growth by inducing oncogene-induced senescence. EMBO Mol Med. 2013;5(9):1367\u201382.","journal-title":"EMBO Mol Med"},{"issue":"4","key":"728_CR26","doi-asserted-by":"publisher","first-page":"330","DOI":"10.2174\/1568009618666181016144855","volume":"19","author":"LJ Yan","year":"2019","unstructured":"Yan LJ, Guo XH, Wang WP, Hu YR, Duan SF, Liu Y, et al. Gene therapy and photothermal therapy of layer-by-layer assembled AuNCs \/PEI\/miRNA\/ HA Nanocomplexes. Curr Cancer Drug Targets. 2019;19(4):330\u20137.","journal-title":"Curr Cancer Drug Targets"},{"issue":"9","key":"728_CR27","doi-asserted-by":"publisher","first-page":"3767","DOI":"10.1021\/acs.molpharmaceut.8b00046","volume":"15","author":"W Wang","year":"2018","unstructured":"Wang W, Huang S, Yuan J, Xu X, Li H, Lv Z, et al. Reverse multidrug resistance in human HepG2\/ADR by Anti-miR-21 combined with hyperthermia mediated by functionalized gold nanocages. Mol Pharm. 2018;15(9):3767\u201376.","journal-title":"Mol Pharm"},{"key":"728_CR28","doi-asserted-by":"publisher","first-page":"399","DOI":"10.2147\/IJN.S84927","volume":"11","author":"Y Zhu","year":"2016","unstructured":"Zhu Y, Liang G, Sun B, Tian T, Hu F, Xiao Z. A novel type of self-assembled nanoparticles as targeted gene carriers: an application for plasmid DNA and antimicroRNA oligonucleotide delivery. Int J Nanomed. 2016;11:399\u2013410.","journal-title":"Int J Nanomed"},{"issue":"14","key":"728_CR29","doi-asserted-by":"publisher","first-page":"3808","DOI":"10.7150\/thno.25255","volume":"8","author":"X Zheng","year":"2018","unstructured":"Zheng X, Zhang F, Zhao Y, Zhang J, Dawulieti J, Pan Y, et al. Self-assembled dual fluorescence nanoparticles for CD44-targeted delivery of anti-miR-27a in liver cancer theranostics. Theranostics. 2018;8(14):3808\u201323.","journal-title":"Theranostics"},{"key":"728_CR30","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.actbio.2015.07.020","volume":"25","author":"S Gao","year":"2015","unstructured":"Gao S, Tian H, Guo Y, Li Y, Guo Z, Zhu X, et al. miRNA oligonucleotide and sponge for miRNA-21 inhibition mediated by PEI-PLL in breast cancer therapy. Acta Biomater. 2015;25:184\u201393.","journal-title":"Acta Biomater"},{"issue":"3","key":"728_CR31","doi-asserted-by":"publisher","first-page":"e60034","DOI":"10.1371\/journal.pone.0060034","volume":"8","author":"F Zhi","year":"2013","unstructured":"Zhi F, Dong H, Jia X, Guo W, Lu H, Yang Y, et al. Functionalized graphene oxide mediated adriamycin delivery and miR-21 gene silencing to overcome tumor multidrug resistance in vitro. PLoS ONE. 2013;8(3):e60034.","journal-title":"PLoS ONE"},{"issue":"1","key":"728_CR32","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ajps.2018.10.006","volume":"15","author":"S Javanmardi","year":"2020","unstructured":"Javanmardi S, Tamaddon AM, Aghamaali MR, Ghahramani L, Abolmaali SS. Redox-sensitive, PEG-shielded carboxymethyl PEI nanogels silencing MicroRNA-21, sensitizes resistant ovarian cancer cells to cisplatin. Asian J Pharm Sci. 2020;15(1):69\u201382.","journal-title":"Asian J Pharm Sci"},{"issue":"4","key":"728_CR33","doi-asserted-by":"publisher","first-page":"e1800445","DOI":"10.1002\/mabi.201800445","volume":"19","author":"Y Dai","year":"2019","unstructured":"Dai Y, Zhang X. MicroRNA delivery with bioreducible polyethylenimine as a non-viral vector for breast cancer gene therapy. Macromol Biosci. 2019;19(4):e1800445.","journal-title":"Macromol Biosci"},{"issue":"4","key":"728_CR34","doi-asserted-by":"publisher","first-page":"360","DOI":"10.3109\/1061186X.2014.1000336","volume":"23","author":"H Song","year":"2015","unstructured":"Song H, Oh B, Choi M, Oh J, Lee M. Delivery of anti-microRNA-21 antisense-oligodeoxynucleotide using amphiphilic peptides for glioblastoma gene therapy. J Drug Target. 2015;23(4):360\u201370.","journal-title":"J Drug Target"},{"issue":"4","key":"728_CR35","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1158\/1541-7786.MCR-09-0443","volume":"8","author":"J Szczyrba","year":"2010","unstructured":"Szczyrba J, Loprich E, Wach S, Jung V, Unteregger G, Barth S, et al. The microRNA profile of prostate carcinoma obtained by deep sequencing. Mol Cancer Res. 2010;8(4):529\u201338.","journal-title":"Mol Cancer Res"},{"issue":"6","key":"728_CR36","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1158\/1541-7786.MCR-10-0573","volume":"9","author":"J Szczyrba","year":"2011","unstructured":"Szczyrba J, Nolte E, Wach S, Kremmer E, Stohr R, Hartmann A, et al. Downregulation of Sec23A protein by miRNA-375 in prostate carcinoma. Mol Cancer Res. 2011;9(6):791\u2013800.","journal-title":"Mol Cancer Res"},{"issue":"3","key":"728_CR37","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1038\/bjc.2013.313","volume":"109","author":"S Wach","year":"2013","unstructured":"Wach S, Nolte E, Theil A, Stohr C, Hartmann A, et al. MicroRNA profiles classify papillary renal cell carcinoma subtypes. Br J Cancer. 2013;109(3):714\u201322.","journal-title":"Br J Cancer."},{"issue":"3","key":"728_CR38","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1002\/ijc.26064","volume":"130","author":"S Wach","year":"2012","unstructured":"Wach S, Nolte E, Szczyrba J, Stohr R, Hartmann A, Orntoft T, et al. MicroRNA profiles of prostate carcinoma detected by multiplatform microRNA screening. Int J Cancer. 2012;130(3):611\u201321.","journal-title":"Int J Cancer"},{"key":"728_CR39","first-page":"3","volume":"11","author":"B Linder","year":"2019","unstructured":"Linder B, Weirauch U, Ewe A, Uhmann A, Seifert V, Mittelbronn M, et al. Therapeutic targeting of Stat3 using lipopolyplex nanoparticle-formulated siRNA in a syngeneic orthotopic mouse glioma model. Cancers. 2019;11:3.","journal-title":"Cancers."},{"key":"728_CR40","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jconrel.2019.12.032","volume":"319","author":"P Zhupanyn","year":"2020","unstructured":"Zhupanyn P, Ewe A, Buch T, Malek A, Rademacher P, Muller C, et al. Extracellular vesicle (ECV)-modified polyethylenimine (PEI) complexes for enhanced siRNA delivery in vitro and in vivo. J Control Release. 2020;319:63\u201376.","journal-title":"J Control Release"},{"issue":"8","key":"728_CR41","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1517\/14728222.2015.1057569","volume":"19","author":"P Mussnich","year":"2015","unstructured":"Mussnich P, Rosa R, Bianco R, Fusco A, D\u2019Angelo D. MiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1. Expert Opin Ther Targets. 2015;19(8):1017\u201326.","journal-title":"Expert Opin Ther Targets"},{"issue":"5","key":"728_CR42","doi-asserted-by":"publisher","first-page":"2966","DOI":"10.18632\/oncotarget.3070","volume":"6","author":"A Bhattacharya","year":"2015","unstructured":"Bhattacharya A, Schmitz U, Raatz Y, Schonherr M, Kottek T, Schauer M, et al. miR-638 promotes melanoma metastasis and protects melanoma cells from apoptosis and autophagy. Oncotarget. 2015;6(5):2966\u201380.","journal-title":"Oncotarget"},{"issue":"10","key":"728_CR43","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1038\/emboj.2011.132","volume":"30","author":"M Bar-Eli","year":"2011","unstructured":"Bar-Eli M. Searching for the \u201cmelano-miRs\u201d: miR-214 drives melanoma metastasis. EMBO J. 2011;30(10):1880\u20131.","journal-title":"EMBO J"},{"issue":"7","key":"728_CR44","doi-asserted-by":"publisher","first-page":"11391","DOI":"10.1002\/jcp.27796","volume":"234","author":"H Cai","year":"2019","unstructured":"Cai H, Zhang P, Xu M, Yan L, Liu N, Wu X. Circular RNA hsa_circ_0000263 participates in cervical cancer development by regulating target gene of miR-150-5p. J Cell Physiol. 2019;234(7):11391\u2013400.","journal-title":"J Cell Physiol"},{"issue":"4","key":"728_CR45","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1002\/pros.22572","volume":"73","author":"HC Nguyen","year":"2013","unstructured":"Nguyen HC, Xie W, Yang M, Hsieh CL, Drouin S, Lee GS, et al. Expression differences of circulating microRNAs in metastatic castration resistant prostate cancer and low-risk, localized prostate cancer. Prostate. 2013;73(4):346\u201354.","journal-title":"Prostate"},{"issue":"9","key":"728_CR46","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1007\/s11255-018-1938-2","volume":"50","author":"P Porzycki","year":"2018","unstructured":"Porzycki P, Ciszkowicz E, Semik M, Tyrka M. Combination of three miRNA (miR-141, miR-21, and miR-375) as potential diagnostic tool for prostate cancer recognition. Int Urol Nephrol. 2018;50(9):1619\u201326.","journal-title":"Int Urol Nephrol"},{"issue":"6","key":"728_CR47","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1002\/ijc.29505","volume":"137","author":"S Wach","year":"2015","unstructured":"Wach S, Al-Janabi O, Weigelt K, Fischer K, Greither T, Marcou M, et al. The combined serum levels of miR-375 and urokinase plasminogen activator receptor are suggested as diagnostic and prognostic biomarkers in prostate cancer. Int J Cancer. 2015;137(6):1406\u201316.","journal-title":"Int J Cancer"},{"issue":"4","key":"728_CR48","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1038\/bjc.2011.595","volume":"106","author":"RJ Bryant","year":"2012","unstructured":"Bryant RJ, Pawlowski T, Catto JW, Marsden G, Vessella RL, Rhees B, et al. Changes in circulating microRNA levels associated with prostate cancer. Br J Cancer. 2012;106(4):768\u201374.","journal-title":"Br J Cancer"},{"issue":"1","key":"728_CR49","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.eururo.2014.07.035","volume":"67","author":"X Huang","year":"2015","unstructured":"Huang X, Yuan T, Liang M, Du M, Xia S, Dittmar R, et al. Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer. Eur Urol. 2015;67(1):33\u201341.","journal-title":"Eur Urol"},{"issue":"1","key":"728_CR50","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/s41598-018-36854-7","volume":"9","author":"E Richardsen","year":"2019","unstructured":"Richardsen E, Andersen S, Melbo-Jorgensen C, Rakaee M, Ness N, Al-Saad S, et al. MicroRNA 141 is associated to outcome and aggressive tumor characteristics in prostate cancer. Sci Rep. 2019;9(1):386.","journal-title":"Sci Rep"},{"issue":"1","key":"728_CR51","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/s41598-019-57101-7","volume":"10","author":"AH Zedan","year":"2020","unstructured":"Zedan AH, Osther PJS, Assenholt J, Madsen JS, Hansen TF. Circulating miR-141 and miR-375 are associated with treatment outcome in metastatic castration resistant prostate cancer. Sci Rep. 2020;10(1):227.","journal-title":"Sci Rep"},{"key":"728_CR52","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1186\/s12935-019-0963-2","volume":"19","author":"L Ma","year":"2019","unstructured":"Ma L, Zhai B, Zhu H, Li W, Jiang W, Lei L, et al. The miR-141\/neuropilin-1 axis is associated with the clinicopathology and contributes to the growth and metastasis of pancreatic cancer. Cancer Cell Int. 2019;19:248.","journal-title":"Cancer Cell Int"},{"key":"728_CR53","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.28416","author":"G Han","year":"2019","unstructured":"Han G, Qiu N, Luo K, Liang H, Li H. Downregulation of miroRNA-141 mediates acquired resistance to trastuzumab and is associated with poor outcome in breast cancer by upregulating the expression of ERBB4. J Cell Biochem. 2019. https:\/\/doi.org\/10.1002\/jcb.28416.","journal-title":"J Cell Biochem."},{"issue":"2","key":"728_CR54","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1159\/000438641","volume":"38","author":"Y Gao","year":"2016","unstructured":"Gao Y, Feng B, Han S, Zhang K, Chen J, Li C, et al. The roles of MicroRNA-141 in human cancers: from diagnosis to treatment. Cell Physiol Biochem. 2016;38(2):427\u201348.","journal-title":"Cell Physiol Biochem"},{"key":"728_CR55","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13148-015-0076-2","volume":"7","author":"P Costa-Pinheiro","year":"2015","unstructured":"Costa-Pinheiro P, Ramalho-Carvalho J, Vieira FQ, Torres-Ferreira J, Oliveira J, Goncalves CS, et al. MicroRNA-375 plays a dual role in prostate carcinogenesis. Clin Epigenet. 2015;7:42.","journal-title":"Clin Epigenet"},{"issue":"1","key":"728_CR56","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/JID.2015.355","volume":"136","author":"K Jayawardana","year":"2016","unstructured":"Jayawardana K, Schramm SJ, Tembe V, Mueller S, Thompson JF, Scolyer RA, et al. Identification, review, and systematic cross-validation of microRNA prognostic signatures in metastatic melanoma. J Invest Dermatol. 2016;136(1):245\u201354.","journal-title":"J Invest Dermatol"},{"issue":"5","key":"728_CR57","doi-asserted-by":"crossref","first-page":"101042831770164","DOI":"10.1177\/1010428317701646","volume":"39","author":"S Fogli","year":"2017","unstructured":"Fogli S, Polini B, Carpi S, Pardini B, Naccarati A, Dubbini N, et al. Identification of plasma microRNAs as new potential biomarkers with high diagnostic power in human cutaneous melanoma. Tumour Biol Med. 2017;39(5):1010428317701646.","journal-title":"Tumour Biol Med"},{"issue":"3","key":"728_CR58","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1002\/jso.25163","volume":"118","author":"N Latchana","year":"2018","unstructured":"Latchana N, DiVincenzo MJ, Regan K, Abrams Z, Zhang X, Jacob NK, et al. Alterations in patient plasma microRNA expression profiles following resection of metastatic melanoma. J Surg Oncol. 2018;118(3):501\u20139.","journal-title":"J Surg Oncol"},{"issue":"1","key":"728_CR59","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.bbrc.2019.05.111","volume":"515","author":"X Yang","year":"2019","unstructured":"Yang X, Zhao H, Yang J, Ma Y, Liu Z, Li C, et al. MiR-150-5p regulates melanoma proliferation, invasion and metastasis via SIX1-mediated Warburg Effect. Biochem Biophys Res Commun. 2019;515(1):85\u201391.","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"728_CR60","doi-asserted-by":"publisher","first-page":"317","DOI":"10.3727\/096504018X15228863026239","volume":"27","author":"X Sun","year":"2019","unstructured":"Sun X, Zhang C, Cao Y, Liu E. miR-150 suppresses tumor growth in melanoma through downregulation of MYB. Oncol Res. 2019;27(3):317\u201323.","journal-title":"Oncol Res"},{"key":"728_CR61","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/978-94-007-5590-1_6","volume":"774","author":"M Kunz","year":"2013","unstructured":"Kunz M. MicroRNAs in melanoma biology. Adv Exp Med Biol. 2013;774:103\u201320.","journal-title":"Adv Exp Med Biol"},{"issue":"2","key":"728_CR62","first-page":"1475","volume":"15","author":"J Wan","year":"2018","unstructured":"Wan J, Yang J, Huang Y, Deng L. MicroRNA-150 inhibitors enhance cell apoptosis of melanoma by targeting PDCD4. Oncol Lett. 2018;15(2):1475\u201382.","journal-title":"Oncol Lett"},{"issue":"7","key":"728_CR63","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.biocel.2010.04.010","volume":"42","author":"F Mancini","year":"2010","unstructured":"Mancini F, Di Conza G, Monti O, Macchiarulo A, Pellicciari R, Pontecorvi A, et al. Puzzling over MDM4-p53 network. Int J Biochem Cell Biol. 2010;42(7):1080\u20133.","journal-title":"Int J Biochem Cell Biol"},{"issue":"2","key":"728_CR64","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1038\/onc.2015.76","volume":"35","author":"F Mancini","year":"2016","unstructured":"Mancini F, Pieroni L, Monteleone V, Luca R, Fici L, Luca E, et al. MDM4\/HIPK2\/p53 cytoplasmic assembly uncovers coordinated repression of molecules with anti-apoptotic activity during early DNA damage response. Oncogene. 2016;35(2):228\u201340.","journal-title":"Oncogene"},{"issue":"18","key":"728_CR65","doi-asserted-by":"publisher","first-page":"7027","DOI":"10.1158\/0008-5472.CAN-10-2010","volume":"70","author":"AG Bader","year":"2010","unstructured":"Bader AG, Brown D, Winkler M. The promise of microRNA replacement therapy. Cancer Res. 2010;70(18):7027\u201330.","journal-title":"Cancer Res"},{"key":"728_CR66","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.jconrel.2014.12.030","volume":"200","author":"A Wicki","year":"2015","unstructured":"Wicki A, Witzigmann D, Balasubramanian V, Huwyler J. Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications. J Control Release. 2015;200:138\u201357.","journal-title":"J Control Release"},{"key":"728_CR67","first-page":"e1903637","volume-title":"Sailor MJ","author":"B Kim","year":"2019","unstructured":"Kim B, Park JH. Sailor MJ. Rekindling RNAi Therapy: Materials Design Requirements for In Vivo siRNA Delivery. Advanced materials; 2019. p. e1903637."},{"issue":"2","key":"728_CR68","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.nano.2010.07.005","volume":"7","author":"A Kwok","year":"2011","unstructured":"Kwok A, Hart SL. Comparative structural and functional studies of nanoparticle formulations for DNA and siRNA delivery. Nanomed Nanotechnol Biol Med. 2011;7(2):210\u20139.","journal-title":"Nanomed Nanotechnol Biol Med"},{"issue":"11","key":"728_CR69","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1002\/ijc.28895","volume":"135","author":"A Fromberg","year":"2014","unstructured":"Fromberg A, Rabe M, Aigner A. Multiple effects of the special AT-rich binding protein 1 (SATB1) in colon carcinoma. Int J Cancer. 2014;135(11):2537\u201346.","journal-title":"Int J Cancer"},{"key":"728_CR70","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/1476-4598-10-144","volume":"10","author":"D Schulze","year":"2011","unstructured":"Schulze D, Plohmann P, Hobel S, Aigner A. Anti-tumor effects of fibroblast growth factor-binding protein (FGF-BP) knockdown in colon carcinoma. Mol Cancer. 2011;10:144.","journal-title":"Mol Cancer"},{"key":"728_CR71","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jconrel.2016.03.034","volume":"230","author":"A Ewe","year":"2016","unstructured":"Ewe A, Przybylski S, Burkhardt J, Janke A, Appelhans D, Aigner A. A novel tyrosine-modified low molecular weight polyethylenimine (P10Y) for efficient siRNA delivery in vitro and in vivo. J Control Release. 2016;230:13\u201325.","journal-title":"J Control Release"},{"issue":"4","key":"728_CR72","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1039\/b302257a","volume":"5","author":"W Stopford","year":"2003","unstructured":"Stopford W, Turner J, Cappellini D, Brock T. Bioaccessibility testing of cobalt compounds. J Environ Monit. 2003;5(4):675\u201380.","journal-title":"J Environ Monit"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-020-00728-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12951-020-00728-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-020-00728-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T11:21:31Z","timestamp":1697196091000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnanobiotechnology.biomedcentral.com\/articles\/10.1186\/s12951-020-00728-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,23]]},"references-count":72,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["728"],"URL":"https:\/\/doi.org\/10.1186\/s12951-020-00728-w","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,23]]},"assertion":[{"value":"18 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the local Ethics Committee, AZ-394-14-15122014. Biopsies and samples were taken after informed consent of the patients. All clinical investigations have been conducted according to the principles expressed in the Declaration of Helsinki.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"173"}}